-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Awl6YZYqL/O+IdTU3TtXR5jvtMqKaqlf9lxYerTO595uVkiIn5NDSpLqBn9JVGFs X3ZoNagi1/UpiY9pdeKM1A== 0000891618-00-001208.txt : 20000307 0000891618-00-001208.hdr.sgml : 20000307 ACCESSION NUMBER: 0000891618-00-001208 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20000301 ITEM INFORMATION: ITEM INFORMATION: FILED AS OF DATE: 20000301 FILER: COMPANY DATA: COMPANY CONFORMED NAME: LASERSCOPE CENTRAL INDEX KEY: 0000851737 STANDARD INDUSTRIAL CLASSIFICATION: ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845] IRS NUMBER: 770049527 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: SEC FILE NUMBER: 000-18053 FILM NUMBER: 558563 BUSINESS ADDRESS: STREET 1: 3052 ORCHARD DR CITY: SAN JOSE STATE: CA ZIP: 95134 BUSINESS PHONE: 4089430636 8-K 1 FORM 8-K 1 SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): MARCH 1, 2000 LASERSCOPE (Exact name of Registrant as specified in its charter) CALIFORNIA 0-18053 77-0049527 (State or other jurisdiction of (Commission File Number) (I.R.S. Employer incorporation or organization) Identification No.)
3052 ORCHARD DRIVE SAN JOSE, CA 95134 (Address of principal executive offices) (Zip code) (408) 943-0636 (Registrant's telephone number, including area code) NOT APPLICABLE (Former name or former address, if changed since last report) 2 ITEM 5. OTHER EVENTS (a) On February 22, 2000 Laserscope (the "Company") issued a press release announcing that it had completed a private placement of subordinate convertible debentures providing net proceeds to the Company of approximately $2.9 million. The placement to affiliates of Renaissance Capital Group, Inc., was managed by Taglich Brothers Inc. ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS (a) Not applicable. (b) Not applicable. (c) Exhibits. -------- 20.1 Press Release dated February 22, 2000 announcing the private placement. [See Exhibit Index.] 3 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. LASERSCOPE (Registrant) Date: March 1, 2000 By: /s/ Dennis Lalumandiere ----------------------- Dennis LaLumandiere Vice President, Finance, Chief Financial Officer and Assistant Secretary 4 INDEX TO EXHIBITS
SEQUENTIALLY EXHIBIT NUMBERED NUMBER DESCRIPTION PAGE - ------- ----------- ------------ 20.1 PRESS RELEASE DATED FEBRUARY 22, 2000 ANNOUNCING 5 THE PRIVATE PLACEMENT.
EX-20.1 2 EX-20.1 1 Exhibit 20.1 LASERSCOPE COMPLETES SECOND PRIVATE FINANCING SAN JOSE, Calif.--(BW HealthWire)--Feb. 22, 2000--Laserscope (Nasdaq: LSCP - news) today announced that it completed a private placement of subordinate convertible debentures with net proceeds to the Company of approximately $2.9 million. The placement to affiliates of Renaissance Capital Group, Inc., was managed by Taglich Brothers, Inc. (s/k/a Taglich Brothers, D'Amadeo, Wagner & Company, Incorporated). The debentures mature seven years from issuance and bear an interest rate of 8.00%. For the first three years, installments will consist of monthly interest payments only. The debentures are convertible into common stock of the Company, with an initial conversion price, which is subject to adjustment, of $1.25. On January 18, 2000 the Company also completed a private placement of common stock providing net proceeds to the Company of approximately $1.8 million. The proceeds from both placements will be used for general corporate purposes. Laserscope designs, manufactures, sells and services on a worldwide basis an advanced line of medical laser systems and related energy delivery devices for the office, outpatient surgical center, and hospital markets. More information about Laserscope can be found on the Company's Web Site at www.laserscope.com. Except for historical information presented, the matters discussed in this announcement may contain forward-looking statements that involve risks and uncertainties. These risks are detailed from time to time in the Company's public disclosure filings with the U.S. Securities and Exchange Commission (SEC). Copies of Laserscope's most recent forms 10K and 10Q are available upon request from its Investor Relations Department. Contact: Laserscope Eric Reuter, 408/943-0636 (President & CEO) Dennis LaLumandiere, 408/943-0636 (CFO) -----END PRIVACY-ENHANCED MESSAGE-----